Related Experiment Video
Updated: Aug 15, 2025
08:55
Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing
Published on: January 20, 2023
11.7K
Lipid Nanoparticle Composition Drives mRNA Delivery to the Placenta
Biorxiv : the Preprint Server for Biology
|January 4, 2023
Summary
Researchers developed novel ionizable lipid nanoparticles (LNPs) for safe mRNA delivery to the placenta. These LNP platforms show potential for treating placental dysfunction and related pregnancy complications.
Area of Science:
- Biomedical Engineering
- Obstetrics and Gynecology
- Molecular Biology
Background:
- Ionizable lipid nanoparticles (LNPs) are advanced mRNA delivery systems, crucial for COVID-19 vaccines and protein therapies.
- Current LNP technology lacks safe and effective placental mRNA delivery for treating placental dysfunction.
- Targeting placental dysfunction requires novel delivery systems for therapeutic mRNA.
Approach:
- Developed and optimized LNPs for enhanced mRNA delivery to placental trophoblasts in vitro and in vivo.
- Utilized Design of Experiments to investigate LNP composition (lipid type, molar ratios) for optimal delivery.
- Evaluated LNP toxicity in pregnant mice and fetuses.
Key Points:
- A specific ionizable lipid and phospholipid combination in LNPs significantly improved in vitro trophoblast transfection.
- One LNP formulation demonstrated superior placental growth factor mRNA delivery in pregnant mice.
- Therapeutic protein synthesis and secretion were confirmed following LNP-mediated mRNA delivery.
Conclusions:
- LNPs are a feasible platform for targeted placental mRNA delivery.
- Developed high-performing, non-toxic LNPs for potential therapeutic applications in placental dysfunction.
- This LNP platform may offer novel treatments for pregnancy complications arising from placental dysfunction.
